Zimbabwe has rejected a significant American health deal valued at 367 million US dollars (£272m) spanning five years because of Washington's request for sensitive information.
This move was revealed following a official document from December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the deal was "lopsided".
A government spokesperson has since explained that the United States was requesting biological samples for research and commercial purposes while refused to share the benefits from any future treatments.
"We will now turn to the difficult and regrettable task of scaling back our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had donated over $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for further negotiations to secure a agreement suitable to all parties so the country's vital HIV programme can continue.
Broader Context
Zimbabwe's decision follows a comparable situation in neighbouring Kenya, where a high court halted a similar deal with the US following concerns were raised about the safety of Kenyans' health data.
Since returning to the presidency last year, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
The agency had overseen aid for the US government, but Trump claimed its expenditure was "inefficient" and his government was seeking direct bilateral agreements to boost transparency and responsibility.
Based on statements, 16 African countries have so far agreed to these new health pacts, representing over $18.3bn of fresh investment.
Specifics of the Rejected Deal
This assistance for Zimbabwe would have supported "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this cooperation could have provided significant advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving antiretroviral therapy through American-funded programmes," Tremont added.
However, government spokesperson Nick Mangwana said the arrangement was "unfair".
"Our nation was requested to surrender its biological resources and data indefinitely, with no equivalent assurance of access to any scientific breakthroughs – like new medicines or tests – that could result from that provided information," his statement read.
"Put simply, our country would provide the raw materials for medical research without any certainty that the end products would be accessible to our population if a future health crisis arise."
Sovereignty and Global Health
Mangwana further said that the US's withdrawal from the global health body and its push of bilateral deals were upending systems previously established via the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing framework designed to manage potential global health emergencies.
"This system is intended to ensure that when a nation provides its information, the resulting advantages – including medicines and cures – are distributed fairly, not monopolised exclusively by those with the capability to develop them."
These objections regarding the US deal "should not be misconstrued as hostility towards the US," he added.
"We are open to continued discussions with our American counterparts on how subsequent co-operation could be structured in a manner that respects the independence and interests of each country."
Health Experts Reaction
A leading public health body said it recognised the government's concerns, but suggested that negotiations must proceed since much of the nation's Aids initiatives were funded by foreign aid.
"If technical issues arise, such as those relating to information security or agreement terms, these can often be resolved via technical clarification and negotiated safeguards," the group commented.
The halted deal underscores the continuing debate between receiving crucial foreign assistance and protecting national sovereignty in an increasingly data-driven world.